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Abstract
Objectives—To provide a brief overview of disparities across the spectrum of breast cancer 
incidence, treatment, and long-term care during the survivorship period.
Data sources—Review of the literature including research reports, review papers and clinically 
based papers available through PubMed and CINAHL.
Conclusion—Minority women generally experience worse breast cancer outcomes despite a 
lower incidence of breast cancer than whites. A variety of factors contribute to this disparity, 
including advanced stage at diagnosis, higher rates of aggressive breast cancer subtypes, and lower 
receipt of appropriate therapies including surgery, chemotherapy, and radiation. Disparities in 
breast cancer care also extend into the survivorship trajectory, including lower rates of endocrine 
therapy use among some minority groups as well as differences in follow-up and survivorship 
care.
Implications for Nursing Practice—Breast cancer research should include improved minority 
representation and analyses by race and ethnicity and socioeconomic status. While we cannot yet 
change the biology of this disease, we can encourage adherence to screening and treatment and 
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help address the many physical, psychological, spiritual and social issues minority women face in 
a culturally sensitive manner.
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The burden of breast cancer is not shared equally among all women in the United States. 
Non-Hispanic white women have a 5-year survival rate of 88.6% while African American 
women have a 78.9% rate, the lowest of all minority groups. Other variations in 5-year 
survival rates include Hispanic/Latina women (87%), Asian women (91.4%), and American 
Indian/Alaska Native American women (85.4%).1
Most of the research that has been done on minority breast cancer survivors focuses on the 
differences between non-Hispanic white women and African American women. Even 
though black women now receive screening mammography at least as often as white 
women, there remains a persistent problem of health disparities in breast cancer care and 
outcomes.2-7 Mortality rates remain higher among black women despite the fact that breast 
cancer incidence is higher in white women.1 Such data suggest that racial differences in 
biology, receipt of appropriate and timely treatment and follow-up care, and other non-
cancer-related conditions may account for differences in all-cause and breast cancer-specific 
mortality.3, 4, 8-10 This article will explore why these variations may exist across the breast 
cancer care continuum. (Table 1)
Epidemiology
Decades of accumulated evidence supports the arguments that differences exist in tumor 
behavior and morphology,2-5, pharmacogenetic responses to therapy13, socioeconomic 
status, access to early screening and treatment11, 14, 15, and differences in patient-level 
behavioral factors.1, 11, 12 All may contribute to differences in breast cancer outcomes by 
race (Figure 1)16.
Epidemiology of Breast Cancer by Race and Age
Black women have a 40% higher likelihood of death due to breast cancer than white women, 
suggesting that racial disparities may play an important role in health outcomes.1 Age and 
breast cancer are closely and meaningfully correlated with the median age at breast cancer 
diagnosis at 62 years 17, 18 Younger women (< age 50) often have more aggressive tumors 
and lower survival rates, whereas older women typically have slower growing tumors with a 
better prognosis.17, 18 African American women are more often diagnosed at a younger age, 
when the disease tends to have a worse prognosis. For black women under the age of 35, the 
incidence of invasive breast cancer is twice that of white women, and breast cancer mortality 
in this group is three times that of age-matched white women. A crossover occurs around the 
time of menopause with incidence rates among older white women surpassing rates of older 
black women.17, 19, 20 Notably mortality rates remain higher in black women regardless of 
age.
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Younger women and African American women also have a greater burden of triple-negative 
breast cancers (i.e., estrogen receptor [ER], progesterone receptor [PR], and human 
epidermal growth factor receptor 2 [HER2/neu] protein expression negative), which confers 
a poorer prognosis 20-22
Etiology and Biologic Risk Factors by Race
The risk of developing breast cancer is related to a number of factors, including age, gender, 
race/ethnicity, familial history of breast cancer, cumulative endogenous and exogenous 
hormone exposure, inherited mutations in breast cancer genes 1 and 2 (BRCA1, BRCA2) 
and other genes, high breast density, radiation exposure, diet, exercise, and post-menopausal 
obesity, many of which vary by race.18,19
Biological factors may also contribute in part to racial/ethnic differences observed in breast 
cancer. Biomarkers, histological features, and tumor behavior of breast cancers vary by race/
ethnicity.4, 23 These findings further support the argument that biological differences in 
breast cancer exist between racial groups.
Screening Patterns
Despite the accumulating evidence for genetic and molecular biologic explanations for 
cancer aggressiveness, black women still have worse outcomes, even after controlling for 
ER, PR, and HER2/neu status and BRCA1 and BRCA2 mutations. Much of this difference 
was attributed historically to poor access to and follow-up after screening 
mammography.9, 23 However African American women have been receiving screening 
mammography at comparable rates to white women for a decade or more. Differences in 
mortality by race persist even when controlling for later stage at diagnosis due to omission 
of or delayed receipt of screening mammography. Thus, it is unlikely that screening 
differences explain racial differences in outcomes in the current era of breast cancer.7
Disparities in Treatment
While pre-diagnosis factors including differences in tumor biology and presenting stage 
certainly contribute to disparities in breast cancer outcomes, persistent racial gaps in stage-
specific and subtype-specific survival suggest that other post-diagnosis factors also play an 
important role. Disparities have been documented across the treatment spectrum including 
surgery, radiation, chemotherapy and endocrine therapy.
Differences in Surgery and Radiation Therapy
In the 1980's and 90's, research on surgical treatment disparities focused on lower rates of 
breast conservation surgery among non-white women. The overall use of breast 
conservation surgery has increased over time, and the racial gap in access appears to have 
narrowed.24 However, in a recent national study of Medicare beneficiaries, African 
American and other non-white women remain modestly less likely than whites to undergo 
breast conserving surgery rather than mastectomy, after adjustment for other clinical and 
demographic factors.25 Other factors associated with lower likelihood of breast conserving 
surgery include geographic region, with rates being lowest in the South and highest in the 
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Northeastern United States. Other factors include lower availability of radiation oncologists 
in the area of residence, higher county-level poverty, lower educational attainment, and 
residing in a rural rather than metropolitan area.25 These data suggest that structural factors 
affect access to care rather than race, and may be primary drivers of surgical treatment 
disparities in the modern era.
Interestingly, in a survey-based study of a diverse group of breast cancer patients, greater 
patient involvement in decision-making (compared to shared or passive decision-making) 
was associated with higher likelihood of receiving mastectomy among all racial groups, 
including African Americans, low- and high-acculturated Latinas, and whites.24 Thus, 
patient preference for treatment perceived as more aggressive or risk-reducing may also 
decrease uptake of breast conserving surgery, regardless of race.
Other research on surgical disparities has focused on management of the axilla. Surgical 
staging of the axilla is a standard of care in breast cancer treatment, but advances in the field 
in the past decade support the less morbid surgical alternative of sentinel lymph node biopsy 
(SLNB).26 SLNB rather than full axillary dissection is the preferred option in most women 
with early stage disease. However, there was a consistently lower likelihood of receiving 
SLNB among African American women. 26 These findings suggest that disparities in the 
receipt of SLNB may be mediated by features of the institution that would logically lead to 
earlier adoption of innovative treatments, and geographic differences.
Significant gaps also occur in the access of poor and minority women to appropriate 
radiation therapy facilities. Radiation following breast conserving therapy is the standard of 
care for women, but is often delayed or missed in vulnerable populations. African American 
race, living in rural Appalachia, lack of insurance, and age >70 were all associated with 
lower rates of radiation following breast conserving surgery.27 This treatment disparity had 
a measurable effect on patient outcomes: not receiving radiation in this study was associated 
with lower overall survival at 10 yrs. In similar studies of Surveillance, Epidemiology and 
End Results (SEER) Medicare patients, related factors emerged.28,29 Non-white race, rural 
compared to urban residence, older age, and greater burden of co-morbidities were all 
associated with lower likelihood of receiving appropriate radiation.28,29 In one study, 
surgeon factors were also significant predictors of receiving radiation including gender 
(patients of female surgeons more often received treatment), US-trained, and holding an MD 
rather than a DO degree.28 As with other treatment disparities, these data suggests that the 
clinical site and provider of care may be drivers of differential treatment.
Data are also available regarding disparities in breast reconstruction following mastectomy. 
Reconstruction rates after mastectomy varied significantly by race, with 41% of whites, 34% 
of African Americans, 41% of highly-acculturated Latinas, and only 13.5% of low-
acculturated Latinas undergoing reconstruction.30
Differences in Chemotherapy
In recent studies minority women appeared to be equally likely to receive adjuvant 
chemotherapy compared to their white counterpart.31,32 However, in one study minority 
women appeared to fare worse in the timeliness and completion of treatment, with both 
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Hispanics and African Americans being more likely than white women to have delays in 
chemotherapy.33 African American women more often fail to complete treatment14 and 
more often receive non-standard regimens or reduced doses.34 In addition, completion rates 
for trastuzumab-based chemotherapy, which involves a year of intravenous treatment and 
significantly improves outcomes in HER2 positive breast cancer, are dramatically lower 
among African American women whereas Hispanic women appear equally likely to 
complete therapy compared to whites.14 These differences may relate to the significant 
social and financial stresses imposed by chemotherapy, such as extended time off work and 
transportation to frequent medical visits, but evidence to support this hypothesis is lacking.
Differences in Endocrine Therapy
Oral anti-estrogen medications including anti-estrogens and aromatase inhibitors are the 
standard of care for long-term prevention of recurrence among women with hormone-
receptor positive breast cancers. These drugs are relatively inexpensive compared to 
chemotherapy and trastuzumab, non-toxic yet potent treatment, and easy to take at home. 
Unfortunately, medication adherence to endocrine therapy is a significant problem in the 
breast cancer population, and emerging evidence suggests that this issue may be more 
problematic in disadvantaged women. Two studies of Medicaid populations have found 
extremely low rates of endocrine therapy use in this group, with only 50% of eligible 
patients filling a prescription within one year35, and 50% of therapy initiators becoming 
non-adherent by year four.36
In the broader population, a recent study in a privately insured cohort found significantly 
lower rates of endocrine therapy initiation among African American compared to white 
women.37 Ongoing work by our group suggests that adherence after initiation is also low 
among young African American women. These findings constitute a need for the 
development of targeted interventions to improve adherence and breast cancer outcomes 
among poor and non-white women. Data on endocrine therapy adherence among minority 
populations other than African Americans is limited, but one study suggested that extremes 
of age (oldest and youngest patients) and increasing co-morbidity were associated with 
lower likelihood of completing therapy, while Asian compared to white women were 
associated with a higher likelihood of completion.38
Survivorship Care
A number of disparities exist in care during and beyond the initial treatment for breast 
cancer including health maintenance, side effect management, prevention of second cancers, 
and health promotion. For example, differences were noted in preventive care; black women 
were less likely to receive a flu vaccine, cholesterol screening, or bone density after a breast 
cancer diagnosis than white women. 39 Comorbid illnesses also varied by race and ethnicity 
with arthritis highest in whites (55.2%), and hypertension (71.1%) and diabetes (30.1%) 
higher in blacks.40 White women were more likely to be higher alcohol users and former 
smokers while black women were more likely to be obese five years or more after 
diagnosis.40 Quality of life was influenced by unemployment, being uninsured, having 1-2 
comorbidities, higher life disruption, and daily stress. However, no differences in 
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survivorship outcomes were noted between African American and non-Hispanic white 
women.41, 42
Symptoms
Common symptoms alone or in combination after breast cancer treatment include fatigue, 
depression, anxiety, pain, sleep disturbance, pain, and cognitive dysfunction43, 44. Of these 
symptoms, fatigue, depression and pain had the greatest impact on overall quality of life 
leading to poorer health status and worse functioning.44 Sleep was worse in minority women 
and was positively correlated with fatigue and depression.45 Black women also had higher 
rates of moist desquamation when treated with radiation therapy in addition to women who 
were obese and postmenopausal.46
After treatment physical activity was associated with fewer symptoms including fatigue and 
pain and better physical functioning and quality of life; findings were similar for non-
Hispanic white and Hispanic women with breast cancer 47 However, fewer African 
American women met recommended levels for physical activity48 and had lower physical 
functioning. Mental health in African American women was positively correlated with 
social support but white women were not.
Financial Impact
The financial impact of having breast cancer was higher in low income women as they 
experienced higher job loss or longer delays in return to work after diagnosis.49 Minority 
women were more likely to be manual laborers and more likely to lose their job or stop 
working after their breast cancer.50 Latina women who received chemotherapy were also 
more likely to lose their job than white women.50 Jobs with less work schedule flexibility 
were detrimental to continued work regardless of other sociodemographic or treatment 
characteristics. In addition, being unemployed contributed to poorer mental health.42
Hispanic/Latina
In a systematic review of 22 quality of life studies in Latina women with breast cancer, 51 
quality of life was lower than in non-Latina white, black or Asian American women.51 This 
included poorer emotional functioning, greater fear of recurrence, depression, and physical 
and social functioning.51 These differences were more pronounced in women with low 
acculturation. Another review of 37 studies of health-related quality of life in Latina 
survivors of breast cancer also reported poorer emotional and physical domains.52
Native Americans
Burnhansstipanov and colleagues surveyed 266 Native American breast cancer survivors 
with the help of Native American patient advocates.53 They evaluated their cross-sectional 
study by time since diagnosis and found significant differences in physical quality of life 
between those diagnosed less than 5 years (greatest impact in first year from diagnosis), and 
5 years and beyond.53 The most significant symptoms included fatigue, weakness, anemia, 
pain, neuropathy, appetite and infections. Many respondents reported difficulty accessing 
and paying for cancer care.53 In comparison with non-Native cancer survivors, Native 
Americans scored lower for physical and social domains, similar for psychological domains, 
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and higher in spiritual quality of life domains.53 The development of a culturally-specific 
cancer support with education program, Native American Cancer Survivor Support Circles, 
increased participants' confidence in their abilities to cope with their cancer.54
Asian
Wen and colleagues55 conducted a systematic review on Asian Americans breast cancer 
experiences and health related quality of life. There was significant variation within 
subgroups but the authors identified many unmet physical and emotional needs in the 26 
studies they evaluated.55 Factors that influenced these women's well-being included their 
level of acculturation as determined by English proficiency and length of residency in the 
US.55
Many of the existing evidence-based interventions to help breast cancer survivors are not 
culturally or linguistically appropriate, limiting their effectiveness in the Asian American 
population. Chinese immigrant women were less likely to report physical distress or have 
problems resolved than US-born Chinese and non-hispanicwhite women.56
National Efforts to Improve Survivorship Care
The National Cancer Institute funded 25 Community Networks Programs to increase 
awareness of, and access to cancer screening in diverse populations. Some groups also 
developed programs to enhance survivorship for their specific community.57 From these 
experiences, they identified four elements for building survivorship programs for diverse 
groups: 1) engaging survivors from diverse groups in program planning and delivery; 2) 
involving survivors in research to enhance understanding, 3) improving well-being of 
diverse groups, and 4) respecting diverse cultures by attending to spirituality, storytelling, 
cultural values, and ceremony.57
Conclusion
We have identified a number of areas across the cancer continuum where disparities 
contribute to poorer outcomes for women with breast cancer. (Table 1) The least advantaged 
women appear to have more issues in facing and living with their breast cancer. The 
magnitude of survivorship problems faced by minority groups are not as well-defined or 
studied but include risk factors, screening, diagnosis and treatment, and survivorship beyond 
treatment. Each of these areas may need to be targeted to begin to close the gaps in quality 
of life and survival. We need to conduct more longitudinal studies with broad diverse 
samples to better identify how disparities influence these outcomes. Breast cancer studies 
should use race/ethnicity and income as covariates when analyzing their data to contribute to 
our understanding of how disparities affect outcomes. While nurses cannot alter the biology 
or many of the risk factors related to the development of breast cancer, they can help women 
adhere to screening and their treatment, identify and manage associated symptoms, and 
empower women in culturally sensitive ways to live their lives after their cancer.
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Table 1
Sources of racial/ethnic disparities across the breast cancer care continuum
Etiology/Risk Factors for 
Breast Cancer








• Genetic variation 
(e.g., BRCA1/2 
mutations)
• Adiposity, diet, 
exercise
• Screening practices












• Side effect 
management
• Palliative treatment 
and supportive care
• Management of 
symptoms post-
treatment
• Prevention of second 
cancers
• Surveillance
• Receipt of preventive 
services
• Management of non-
cancer conditions
• Quality of life
• Financial toxicity
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